These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 12559038)

  • 1. The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer.
    Orlowski RZ; Dees EC
    Breast Cancer Res; 2003; 5(1):1-7. PubMed ID: 12559038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the ubiquitin-proteasome pathway in breast cancer.
    Cardoso F; Ross JS; Picart MJ; Sotiriou C; Durbecq V
    Clin Breast Cancer; 2004 Jun; 5(2):148-57. PubMed ID: 15245620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecule of the month. Bortezomib.
    Drug News Perspect; 2003 Jun; 16(5):324. PubMed ID: 12942163
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of proteasome inhibitors in solid tumors.
    Park DJ; Lenz HJ
    Ann Med; 2004; 36(4):296-303. PubMed ID: 15224656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib and its role in the management of patients with multiple myeloma.
    Orlowski RZ
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential for proteasome inhibition in the treatment of cancer.
    Adams J
    Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathways that modify tumor radiation response.
    Pervan M; Pajonk F; Sun JR; Withers HR; McBride WH
    Am J Clin Oncol; 2001 Oct; 24(5):481-5. PubMed ID: 11586100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].
    Satou Y; Matsuoka M
    Nihon Rinsho; 2004 Jul; 62(7):1363-7. PubMed ID: 15283157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition in cancer: development of PS-341.
    Adams J
    Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the proteasome inhibitor bortezomib in hematologic malignancies.
    Goy A; Gilles F
    Clin Lymphoma; 2004 Mar; 4(4):230-7. PubMed ID: 15072615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib as a potential treatment for prostate cancer.
    Papandreou CN; Logothetis CJ
    Cancer Res; 2004 Aug; 64(15):5036-43. PubMed ID: 15289299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.
    Soucy TA; Smith PG; Rolfe M
    Clin Cancer Res; 2009 Jun; 15(12):3912-6. PubMed ID: 19509147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First proteasome inhibitor approved for multiple myeloma.
    Twombly R
    J Natl Cancer Inst; 2003 Jun; 95(12):845. PubMed ID: 12813164
    [No Abstract]   [Full Text] [Related]  

  • 14. A review of the proteasome inhibitor bortezomib in multiple myeloma.
    Richardson PG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1321-31. PubMed ID: 15163277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer.
    Lipkowitz S
    Breast Cancer Res; 2003; 5(1):8-15. PubMed ID: 12559039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proteasome as a target for cancer therapy.
    Voorhees PM; Dees EC; O'Neil B; Orlowski RZ
    Clin Cancer Res; 2003 Dec; 9(17):6316-25. PubMed ID: 14695130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
    Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of the proteasome inhibitor Velcade (Bortezomib).
    Adams J; Kauffman M
    Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathways: targeting proteasomal protein degradation in cancer.
    Molineaux SM
    Clin Cancer Res; 2012 Jan; 18(1):15-20. PubMed ID: 22019514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.